Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations
Open Access
- 4 November 2023
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (12) , 2675-2686
Abstract
Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug–drug interactions when co‐administered with CYP3A inhibitors or inducers. The primary objective was to assess the impact of the strong CYP3A inhibitor posaconazole (part 1) and the moderate CYP3A and P‐gp inhibitor diltiazem (part 2) on encorafenib pharmacokinetics in healthy volunteers following a single 50‐mg dose. A total of 32 participants were enrolled (16 each in parts 1 and 2). The area under the curve extrapolated to infinity (AUCinf) and maximum plasma concentration (Cmax) geometric mean for encorafenib increased by 183% and 68.4%, respectively, when co‐administered with posaconazole. Apparent encorafenib clearance decreased from 26.0 to 9.2 L/h when coadministered with posaconazole, and plasma terminal half‐life (t½) of encorafenib increased from 4.3 to 7.3 h. The AUCinf and Cmax geometric mean for encorafenib increased by 83.0% and 44.7%, respectively, when co‐administered with diltiazem. Similarly, the apparent encorafenib clearance decreased from 29.0 to 16.0 L/h when co‐administered with diltiazem, and plasma t½ of encorafenib increased from 6.6 to 7.9 h. There were no deaths, serious adverse events (AEs), or patient discontinuations due to AEs in parts 1 or 2. The most frequently reported treatment‐related AEs were erythema (n = 14; 88%) and headache (n = 11; 69%) in part 1 and headache (n = 7; 44%) in part 2. The results of this study indicate that co‐administration of encorafenib with strong or moderate CYP3A4 inhibitors should be avoided.Keywords
This publication has 15 references indexed in Scilit:
- Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEPAntimicrobial Agents and Chemotherapy, 2016
- Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factorXa inhibitorBritish Journal of Clinical Pharmacology, 2014
- Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteersExpert Opinion on Drug Metabolism & Toxicology, 2011
- Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go?The Journal of Clinical Pharmacology, 2011
- Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteersBiopharmaceutics & Drug Disposition, 2011
- Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteersClinical Therapeutics, 2009
- Effects of oral posaconazole on the pharmacokinetics of sirolimusCurrent Medical Research and Opinion, 2009
- Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and TacrolimusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)Drug Metabolism and Disposition, 2004
- Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem MetabolitesThe Journal of Pharmacology and Experimental Therapeutics, 1997